Impel Pharmaceuticals Inc.
IMPL · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $13 | $1 | $0 | $0 |
| % Growth | 1,794% | – | – | – |
| Cost of Goods Sold | $6 | $1 | $0 | $0 |
| Gross Profit | $6 | -$0 | $0 | $0 |
| % Margin | 48.7% | -3.4% | – | – |
| R&D Expenses | $11 | $21 | $27 | $29 |
| G&A Expenses | $78 | $51 | $18 | $13 |
| SG&A Expenses | $78 | $51 | $18 | $13 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | $0 |
| Operating Expenses | $89 | $71 | $45 | $42 |
| Operating Income | -$83 | -$71 | -$45 | -$42 |
| % Margin | -657.5% | -10,701.5% | – | – |
| Other Income/Exp. Net | -$23 | -$5 | -$0 | -$0 |
| Pre-Tax Income | -$106 | -$77 | -$46 | -$42 |
| Tax Expense | $23 | $0 | $0 | $0 |
| Net Income | -$129 | -$77 | -$46 | -$42 |
| % Margin | -1,023.1% | -11,457.5% | – | – |
| EPS | -5.52 | -5.24 | -3.49 | -3.19 |
| % Growth | -5.3% | -50.1% | -9.4% | – |
| EPS Diluted | -5.52 | -5.24 | -3.49 | -3.19 |
| Weighted Avg Shares Out | 23 | 15 | 13 | 13 |
| Weighted Avg Shares Out Dil | 23 | 15 | 13 | 13 |
| Supplemental Information | – | – | – | – |
| Interest Income | $11 | $2 | $0 | $0 |
| Interest Expense | $14 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$91 | -$70 | -$44 | -$41 |
| % Margin | -721.4% | -10,538.6% | – | – |